Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris With Nodules
NCT00666900 is registered in ClinicalTrials.gov with Dow Pharmaceutical Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris With Nodules
- Lead sponsor
- Dow Pharmaceutical Sciences
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2008
- Completion date
- September 30, 2009
- Enrollment
- 366 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.